National HIV case reporting for the united states a defining moment in the history of the epidemic

New England Journal of Medicine

Volumn 337, Issue 16, 1997, Pages 1162-1167

  Gostin, Lawrence O ^a   Ward, John W ^b   Cornelius Baker, A ^c  

^a GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Natl Assoc of People with AIDS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CASE REPORT; EPIDEMIC; HISTORY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; MONITORING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RETROVIRUS; REVIEW; SURVIVAL;

ANALYTICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANONYMOUS TESTING; CONFIDENTIALITY; DISEASE NOTIFICATION; DISEASE OUTBREAKS; GOVERNMENT REGULATION; HISTORY, 20TH CENTURY; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; PRIVACY; RESOURCE ALLOCATION; RISK ASSESSMENT; UNITED STATES; VULNERABLE POPULATIONS;

EID: 0030761603     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710163371611     Document Type: Article

References (69)

1. Update: trends in AIDS incidence, deaths, and prevalence -United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:165-73.
2. Institute of Medicine. Confronting AIDS: directions for public health, health care, and research. Washington, D.C.: National Academy Press, 1986.
3. Masur H, Michelis MA, Greene JB, et al. An outbreak of community acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysftmction. N Engl J Med 1981;305:1431-8.
4. Francis DP, Curran JW, Essex M. Epidemic acquired immune deficiency syndrome: epidemiologic evidence for a transmissible agent. J Natl Cancer Inst 1983;71:1-4.
5. Bayer R. Private acts, social consequences: AIDS and the politics of public health. New York: Free Press, 1989.
6. Baare Sinoussi F, Chermann JC, Key F, et al. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
7. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and iso lation of cytopathic retroviruses (HTLV-III) from patients with AJDS and at risk for AIDS. Science 1984;224:500-3.
8. Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985;34:1-5.
9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 1996;271:1582-6.
10. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts between 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
11. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
12. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med I996;334:1011-7.
13. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-9.
14. Peckham C, Gibb D. Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995;333:298-302.
15. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA I996;275:1483-8.
16. Update: trends in AIDS incidence -United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:861-7.
17. Update: public health surveillance for HIV infection -United States, 1989 and 1990. MMWR Morb Mortal Wkly Rep 1990;39:853, 859-61.
18. Adult HIV/AIDS confidential case report. CDC50.42A. Bethesda, Md.: Department of Health and Human Services, 1993.
19. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 1997. Vol. 9. No. 1.
20. HIV infection reporting -United States. MMWR Morb Mortal Wkly Rep 1989;38:496-9.
21. Centers for Disease Control and Prevention. Alabama, Arizona, Arkansas, Colorado, Idaho, Indiana, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, Wisconsin, Wyoming. HIV/AIDS Surveillance Report, 1996. Vol. 8. No. 2. 29.
22. Idem. Connecticut and Texas require reporting for pediatrie cases of children less than 13 years old: Oregon requires reporting for pediatrie cases of children less than 6 years of age. HIV/AIDS Surveillance Report, 1996. Vol. 8. No. 2.
23. Burr C. The AIDS exception: privacy vs. public health. Atlantic Monthly. June 1996:57-67.
24. Richardson L. Progress on AIDS treatments brings movement for less secrecy. New York Times. August 21, 1997:A1.
25. Bayer R. Public health policy and the AIDS epidemic: an end to HIV exceptionalism? N Engl J Med 1991;324:1500-4.
26. Angell M. A dual approach to the AIDS epidemic. N Engl J Med 1991;324:1498-500.
27. Steinbrook R. Battling HIV on many fronts. N Engl J Med 1997;337: 779-80.
28. Sweeney P, Fleming PL, Ward JW. Monitoring current HIV transmis-sion to promote prevention: supplementing AIDS surveillance. AIDS 1995;9:645-7.
29. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-805.
30. Buehler JW, Diaz T, Hersh BS, Chu SY. The supplement to HIV AIDS surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep 1996;11 LSuppl 1:133-7.
31. McQuillan GM, Khare M, Karon IM, Sellable CA, Vlahov D. Updateon the seroepidemiology of human immunodeficiency virus in the United States household population: NHANKS III, 1988-1994. J Aequir Immune Detic Syndr Hum Retrovir 1997;14:355-60.
32. CDC Advisory Committee on the Prevention of HIV Infection. External review of CDC's HIV prevention strategies. Atlanta: Centers for Disease Control and Prevention, 1994.
33. Strategic plan for preventing human immunodeficiency virus (HIV) infection. Atlanta: Centers for Disease Control and Prevention, 1992.
34. Position statement: confidential reporting of HIV infection. Atlanta: Council of State and Territorial Epidemiologists, 1997.
35. Ward JW, Fleming PL, Buehler JW. Annotation: what will be the role of HIV infection reporting? Am J Public Health 1994;84:1888-9.
36. Kahn JG. The cost effectiveness of FIIV prevention targeting: how much more bang for the buck? Am J Public Health 1996;86:1709-12.
37. Wortlcy I'M, Fleming PL, Lindegren M-L, Sweeney PA, Davis S. Using HIV/AIDS surveillance to monitor public health efforts to reduce perinatal transmission of HIV. J Aequir Immun Defie Syndr Hum Retrovir 1996;11:205-6.
38. Hoffman RE, Spencer NE, Miller LA. Comparison of partner notiti cation at anonymous and confidential HIV test sites in Colorado. J Aequir Immune Defic Svndr Hum Retrovir 1995;8:406-10.
39. Kamb ML, Rhodes F, Bolan G, et al. Does HIV/STD counseling work? Results from a randomizcd controlled trial (Project Respect). Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997. abstract.
40. HIV counseling, testing, and referral standards and guidelines. Atlanta: Outers for Disease Control and Prevention, 1994.
41. Report of the NIH Panel to Define Principles of Therapy of HIV In lection and guidelines for the use of antiretroviral agents in HIV-infeeted adults. Washington, D.C.: Department of Health and Human Services, 1997.
42. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 diseaseprogression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:477-83.
43. Bayer R, Toomey KH. HIV prevention and the two faces of partner notification. Am J Public Health 1992;82:1158-64.
44. Guide to public health practice: HIV partner notification strategies. Washington, D.C.: Association of State and 'lerritorial Health Officials, 1988.
45. HIV/AIDS and Medicaid: standards of care for new therapies. Mcd icaid Pharm Bull 1996;10:1-6.
46. Pear R. Medicaid may be extended to early treatment of AIDS. New York Times. June 1, 1997:20.
47. Francis DP, Singleton IA. Reporting of HIV l infection through the provision of essential services. J Aequir Immune Detic Syndr 1993;6:285-6.
48. Forbes A. Naming names -mandatory name based HIV reporting: impact and alternatives. AIDS Policy & Law. May 1996:1-4.
49. Should HIV test results he reportable? A discussion of the key policy questions. Washington, D.C.: AIDS Action Foundation, 1993.
50. Hecht FM, Colman S, Lehman IS, et al. Named reporting of HIV: attitudes and knowledge of those at risk. J Gen Intern Med 1997;12:Snppl 1:108. abstract.
51. Hirano D, Geliert GA, Fleming K, Boyd D, Englender SI, Hawks H. Anonymous HIV testing: the impact of availability on demand in Arizona. Am J Public Health 1994;84:2008-10.
52. Kegeles SM, Catania JA, Coates TJ, Pollack LM, Lo B. Many people who seek anonymous HIV antibody testing would avoid it under other cir cumstances. AIDS 1990;4:585-8.
53. Fchrs L], Fleming D, Foster LR, et al. Trial of anonymous versus confidential human immunodeficiency virus testing. Lancet 1988;2:379-82.
54. Meyer PA, Jones JL, Garrison CZ, Dowda H. Comparison of individuals receiving anonymous and confidential testing for HIV. South Med J 1994;87:344-7.
55. Phillips KA. The relationship of 1988 state HIV testing policies to previous and planned voluntary use of HIV testing. J Acquir Immune Detic Syndr 1994;7:403-9.
56. Statement of the National HIV Testing Action Coalition on the Necessity for Maintaining Anonymous HIV Testing Sites in All States. Wash ington, D.C.: HIV Testing Action Coalition, 1997.
57. Fox DM. From TB to AIDS: value conflicts in reporting disease. Has tings Cent Rep 1986;16(6):Suppl:l 1-6.
58. Landry S. AIDS list is out: state investigating breach. St. Petersburg Times. September 20, 1996:51.
59. Tarrant City Hospital District v. Huges, 734 SW2d 675 (Tex App 1987).
60. Public Act 87-763, sec. 693.40(3)(A) (1991).
61. Gostin LO. Health information privacy. Cornell Law Rev 1995;80: 451-528.
62. Gostin LO, Lazzarini Z, Neslund VS, Osterholm Ml'. The publichealth information infrastructure: a national review of the law on health information privacy. JAMA 1996;275:1921-7
63. Whalen v. Roe, 429 U.S. 589 (1977).
64. Edgar H, Sandomire H. Medical privacy issues in the age of AIDS: legislative options. Am J Law Med 1990;16:155-222.
65. 42 U.S.C. 242m(d).
66. Gostin LO. The Americans with Disabilities Act and the U.S. health system. Health Aff (Millwood) 1992;11(3):248-57.
67. McDonald AM, Gertig DM, Crofts N, Kaldor JM. A national surveil lance system tor newly acquired HIV infection in Australia. Am J Public Health 1994;84:1923-8.
68. Smith K, Rix BA, Melbye M. Mandatory anonymous HIV surveillance in Denmark: the first results of a new system. Am J Public Health 1994; 84:1929-32.
69. Morris S, Gray A, Noone A, Wiseman M, Jathanna S. The costs and effectiveness of surveillance ol communicable disease: a case study of HIV and AIDS in England and Wales. J Public Health Med 1996;18:415-22.